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Under suitable conditions, polypeptides which can evoke elements of the in- 
flammatory reaction appear in mammalian plasma or inflammatory exudates. 
These polypeptides, the plasma kinins, increase vascular permeability, contract 
smooth muscle, dilate blood vessels, initiate leukocytic infiltration, and provoke 
pain (1). The kinins are derived from a protein precursor, prokinin or kininogen. 
Several groups of investigators have pointed out that plasmin, the proteolytic 
enzyme or enzymes of plasma which can digest many substrates at neutrality, 
can induce the formation of kinins, either directly or through an action upon 
kallikreinogen (2-8). The presence of kinins was recognized by their ability to 
contract smooth muscles  or dilate  blood vessels.  Curiously, it has  not been 
possible to demonstrate that plasmin increases vascular permeability, one of the 
properties attributed to kinins (9-11). The reasons for this discrepancy are not 
clear. 
In the present study,  the effect of plasmin upon vascular permeability has 
been reexamined. Partially purified plasminogen was prepared in such a  way 
that it was soluble in aqueous media at neutrality, and was relatively deficient 
in Hageman factor. Plasmin derived from this preparation regularly increased 
vascular permeability in guinea pig skin, an effect inhibited by soybean trypsin 
inhibitor. When plasmin was incubated with fractions of plasma rich in pro- 
kinins, permeability-enhancing properties appeared in the mixture. These prop- 
erties could not be blocked by soybean trypsin inhibitor or heparin, suggesting 
that they might be due to the presence of kinins. The possibility must be enter- 
mined that plasmin may contribute to the increase in vascular permeability 
characteristic of the acute inflammatory reaction. 
Materials 
Partially purified plasminogen was prepared by adaptations of methods of Robbins and 
Summaria (12), Cole (13), and Hagan (14) from Cohn fraction 1114 of human plasma.  1 Cohn 
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fraction III4 was chromatographed successively upon columns of hydroxylapatite, carboxy- 
methylcellulose, and  diethylaminoethyl sephadex,  each column  being 24 cm  high and  2.7 
cm in diameter. The protein content of fractions of the ehiate was estimated approximately 
by measuring their ultraviolet absorption at a  wave length of 280 ~  with a  Gilson medical 
electronics ultraviolet absorption meter. 
In a  typical preparation, 8 gm of fraction III4, containing 15 per cent protein, was dis- 
solved in a solution of 0.2 ~r sodium chloride and 0.02 ~¢ L-lysine monohydrochloride (Nutri- 
tional Biochemieals Co., Cleveland) at pH 7.0 and dialyzed overnight against 3 liters of this 
buffer. The fraction was then applied to a  column of hydroxylapatite (hypatite C,  Clarkson 
Chemical  Co.,  Inc.,  Williamsport,  Pennsylvania)  previously  equilibrated  with  the  same 
buffer. The plasminogen was eluted with a  linear gradient of 250 ml each of this buffer and 
of 0.4 x+ potassium phosphate (pH 6.8)  containing 0.02 M L-lysine monohydrochloride. Ma- 
terial containing plasminogen was eluted after approximately  140 ml of buffer had entered 
the column, coincident with the appearance of an asymmetric peak of protein. 
The 230 ml of eluate with maximal plasminogen activity was dialyzed for 8 hours against 
3 liters of 0.01 M sodium acetate (pit 5.2)  and applied to a column of earboxymethylceUulose 
(15)  equilibrated with this buffer. Contaminating protein was ehited with a  linear gradient 
of 125 ml each of 0.01 x+ sodium acetate (pH 5.2)  and 0.01 x¢ sodium acetate (pH 5.2)  in 0.1 
x¢  sodium  chloride;  both  buffers  contained  0.02 ~  L-lysine  monohydrochloride.  Fractions 
containing plasminogen were ehited with a  linear gradient of 150 ml of the sodium acetate- 
sodium chloride-lysine buffer and  150 ml of 0.05 ~  trishydroxymcthylamino-methane (tris), 
0.1 ~  sodium chloride, and 0.02 M L-lysine hydrochloride at pH 9.0. Material containing plas- 
minogen was eluted after 200 ml of the gradient had entered the column. An additional 100 
ml of the final buffer was applied to complete elution. At least three components could be 
identified in  the  fractions containing plasminogen  as  measured  by  ultraviolet absorption 
during chromatography. 
The  active  fractions  were  pooled,  dialyzed  for  2  hours  against  the  tris-lysine-sodium 
chloride buffer and  applied  to  a  column  of  diethylaminoethyl sephadex A-S0  (Pharmacia 
Fine Chemicals, New York). Plasminogen did not adhere to the column and was collected by 
elution with the same buffer. The fractions containing plasminogen were pooled and stored 
at  4°C.  After  dialysis  against  0.15 ~  sodium  chloride solution,  the  plasminogen  could  be 
lyophil~zed without loss.  The solutions of plasminogen were by no means pure, containing 
approximately  75  to  120  Remmert  and  Cohn units per mg of nitrogen, as  determined by 
Kjeldahl analysis. 
In different batches, approximately  10 to 30 per cent of the "plasminogen" was in the 
form of plasmin, measured by the capacity  to  digest casein without further activation. It 
contained trace amounts of clot-promoting materials which shortened the abnormally long 
clotting time of plasma deficient in Hageman factor, as tested by an assay described earlier 
(16).  Assuming that  the clot-promoting activity was  due  to  Hageman  factor,  there were 
approximately 0.0005 units of Hageman factor per unit of plasminogen, one unit of Hageman 
factor being that amount found in one ml of pooled normal human plasma (16). Trace amounts 
of activity assayed as plasma thromboplastin antecedent  (PTA,  factor XI),  Christmas fac- 
tor (factor IX), factor VII, and  Stuart  factor (factor  X)  were  present,  but  there was  no 
measurable  antihemophilic factor (factor  VIII), proaccelerin  (factor  V),  nor  prothrombin 
(factor II), (16,  17). No activity resembling C'1 esterase or Crl subcomponents was detectible. 
Before injection into guinea pig skin, the solution of plasminogen was dialyzed  overnight 
against barbital-saline buffer containing 0.02 ~¢ lysine. 
Crude preparations containing prokiniu were separated from human plasma by two meth- 
ods. In one, the fraction soluble at 4°C at 30 per cent saturation but insoluble at half-satura- 
tion  with  neutral ammonium  sulfate  was  precipitated  from  eitrated  plasma  deficient  in OSCAg D.  P,  ATNOrF  907 
Hageman factor. The precipitate, dissolved in its original volume of water, was dialyzed over- 
night against  barbital-saline buffer and  then  diluted with one-tenth volume of 5 per cent 
sodium ethylenediaminetetraacetic acid (pH 7.0).  Half of the globulin was incubated for 30 
minutes in cellulose nitrate tubes in a water-bath set at 62°C. This procedure is said to deplete 
plasma of kallikreinogen (18, 19) and the precursor of human plasma PF/Dil (20, 21) but to 
leave prokinin intact (19, 22). 
The method just described is subject  to the objection that  the preparation  was heated. 
Prokinin was therefore separated  in a  second way by a  minor adaptation  of the technique 
of Webster and  Pierce  (23).  One hundred  ml of citrated normal human plasma,  separated 
from out-dated bank blood, was diluted to 400  ml with water and  the pH adjusted to 6.0 
with 1 ~s acetic acid. The diluted plasma was stirred with 4 gm of diethylaminoethyl (DEAE)- 
cellulose (selectacel Type 20,  capacity 1.17 meq per gin,  Carl  Schleicher and  Schuell Co., 
Keene,  New Hampshire)  which had  been  equilibrated with 0.005 ~  potassium  phosphate 
(pI-I 6.0).  The filter cake was then ehited three times with 50 ml each of 0.2 x~ potassium 
phosphate (pH 6.0), centrifuging each time at 3500 RP~ for 10 minutes. The combined eluates 
were recentrifuged,  the supernatant  solution dialyzed overnight against  0.005 M potassium 
phosphate  (pH 6.0),  and the precipitate which formed was removed by centrifugation. The 
supernatant  fluid was applied to a  DEAE-cellulose column, 22 cm in height and 2.7  cm in 
diameter, previously equilibrated with the same buffer. The column was eluted successively 
by 100 ml 0.005 ~t and 300 ml of 0.08 ~s potassium phosphate (pH 6.0), and then by a linear 
gradient of 250 ml each of 0.08 and 0.2 ~s potassium phosphate (pH 6.0).  Material containing 
prokinin-like activity was eluted  after approximately 200  ml of the gradient mixture had 
entered the column. Maximal activity, in fractions totalling 125 ml, coincided with the cen- 
tral portion of an almost symmetrical peak of protein, as measured by ultraviolet absorption. 
Although kallikreinogen is said not to adhere to DEAE-cellulose (24), proof that this material 
was not contaminated with kallikreinogen was lacking. 
Streptokinase, "high purity, 9 dissolved in buffer at concentrations of 1000 or 2000 Christen- 
sen  units  per ml,  or purified human  urokinase,  8 dissolved at  various concentrations,  were 
used to change plasminogen to plasmin. The preparation of urokinase used contained 275,000 
"C.T.A." units per mg of nitrogen. 
Soybean ~rypsin inhibitor  (SBTI),  5 rimes crystallized,  (Nutritional Biochemicals Corp., 
Cleveland), was suspended in buffer at a concentration of 2 mg per ml, and diluted suitably 
as needed. 
Epsilon  aminocaproic acid  (Mann  Research Lab.,  Inc.,  New York)  was  dissolved at  a 
concentration of 0.8 ~ in water. 
Heparin 4 (156 Toronto units per rag)  was dissolved in buffer. 
Triprolidi~ hydrochloride (actidil),  5 an antihistaminic agent, was dissolved at a  concen- 
tration of 1.0 rag (calculated as free base) per ml of 0.15 ~  sodium chloride solution. 
Histamine  diphosphate (u.s.P.,  B grade, Calbiochem, Los Angeles)  was dissolved at a con- 
centration of 55 pg per ml of buffer, corresponding to 20 #g of free base per ml. 
Sodium  e~hylotediamit~tetraacet~ acid (EDTA) was dissolved at a  concentration of 5 per 
cent in water and brought to pH 7.4 by the addition of sodium hydroxide. 
s Streptokinase was the gift of the American Cyanamid  Company, Lederle Laboratories 
Division, Pearl River, New York. 
s Urokinase was provided by the Sterling-Winthrop Research Institute,  Rensselaer, New 
York. 
4 Purified heparin was furnished by the Upjohn Company, Kalamazoo, Michigan. 
5 Triprolidine hydrochloride was  the  gift of Burroughs,  Wellcome and  Company,  Inc., 
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Hageman factor, partially purified by a  method described before  (16),  was  dissolved in 
buffer at a  concentration of 4 or 8/~g protein per ml. A single lot, "December 4, 1961", con- 
taining 8 per cent protein and 52 units of Hageman factor per nag of protein was used. Only 
one per cent of the Hageman factor in this preparation was activated, the rest being in the 
form of an inert precursor. 
Crystalline bovine trypsin,  twice crystallized (Worthington Biochemical Corp.,  Freehold, 
New Jersey), was dissolved in buffer just before use. The preparation contained approximately 
50 per cent magnesium sulfate. The concentrations of trypsin recorded are uncorrected for 
this contaminant. 
Hageman/actor-deficient plasma was prepared  from blood obtained from a  patient with 
Hageman trait, to which one-ninth volume of 0.13 ,~ sodium citrate buffer (pH 5.0) had been 
added. 
All dialyses were performed at 4°C in visking no-jax cellophane casings. All centrifugations 
were at 20C. 
Unless otherwise specified, the buret used was 0.025 ~  barbital in 0.125 g  sodium chloride 
solution at pH 7.5. 
Methods 
Vascular permeability was  tested by  the method  of  Miles and  Wilhelm  (25)  in albino 
guinea pigs of either six which usually weighed between 450 and 500 gm. The guinea pigs 
were depilated and injected intravenously with 1.2 ml per kg of body weight of a  5 per cent 
solution of pontamine sky blue 6  X  (E.  I.  Dupont de Nemours and Co.,  Wilmington) in 
0.075 ~t pyrogen-free sodium chloride solution. Beginning within the succeeding 10 minutes, 
unless otherwise noted,  the solutions to  be tested were  injected intracutaneously into the 
dorsum of the guinea pigs in a volume of 0.1 ml, using No. 26 gauge disposable needles (Bec- 
ton,  Dickinson and  Co.,  Rutherford,  New  Jersey)  and silicone-coated tuberculin syringes. 
15 minutes after the last injection, the size of the lesion was estimated as the average of the 
widest diameter and the diameter perpendicular to it.  Permeability-enhancing activity was 
expressed in terms of the average diameter of the lesions in three or four guinea pigs. An oc- 
casional guinea pig reacted with an increase in vascular permeability to any solution con- 
taining human plasma proteins. The values obtained in such "sensitive" guinea pigs were 
not included in  the data presented.  The increase in  vascular permeability which resulted 
from an injection of buffer was  significantly less when disposable needles were used  than 
with stainless steel needles, used in earlier studies. 
An elective blueing dose of material is that amount in a volume of 0.1 ml which produces 
a lesion whose average diameter, 15 minutes after injection, is 6.0 mm (25). 
The  effect of plasmin  upon vascular permeability was  tested  by  activating plasminogen 
with streptokinase or urokinase. In general, equal volumes of plasminogen solution and solu- 
tions of streptokinase or urokinase were incubated at room temperature in cellulose nitrate 
tubes for 15 minutes and then stored in ice for as long as 45 minutes until injected. The in- 
hibitory effect of SBTI upon the activity of plasmin was tested by incubating one volume of 
piasminogen with one-half volume of streptokinaso or urokinase for  15 minutes,  and then 
adding one-half volume of SBTI or buffer. The mixtures were stored in ice until injected. 
The ~'nhibitory effect of epsilon aminocaproic acid upon the activation of plasmin was measured 
by incubating one volume of plasminogen, one-half volume of streptokinase or urokinase, 
and one-half volume of epsilon aminocaproic acid or buffer together at room  temperature 
for 15 minutes and then storing the mixtures in ice. 
The  effect of triprolidine  hydrochloride upon  the  permeabifity-enhancing properties  of 
plasmin was tested by comparing the effect of the intravenous injection of 0.1 ml per kg of 
body weight of this agent, at a  concentration of 1 mg free base per ml, with 0.15 M sodium OSCAR D.  RATNOFF  909 
chloride solution. The triprolidine or sodium chloride solutions were administered with the 
pontamine sky blue dye, before the intracutaneous injection of test substances. The effective- 
ness of the injection of triprolidine was tested by the intracutaneous injection of histamine. 
The effect of plasmin and other enzymes upon crude prokinin, prepared by the method of 
Webster and Pierce (23), was studied by incubating  a mixture of 0.18 ml of "prokinin" solu- 
tion, 0.02 ml of 5 per cent EDTA solution, 0.1 ml of the enzyme to be tested and 0.1 ml of 
buffer in silicone-coated Pyrex tubes (8 mm internal diameter) at 25°C for 30 minutes. The 
mixture was then transferred to an ice-bath and diluted to 2.0 ml with buffer before injection. 
The enzymes tested were plasmin, prepared by mixing an equal volume of plasminogen (2.5 
units per ml) and streptokinase  (2000 units per ml), trypsin, 0.1 mg per ml and Hageman 
factor, 8#g of protein per ml, the concentrations referring to the solutions before their addi- 
tion to prokiuin. The effect of SBTI and heparin upon the action of these enzymes was tested 
by substituting these inhibitors for buffer in both the initial mixture and the subsequent 
diluting fluid. The concentration of SBTI was maintained at 250/#g per ml, and of heparin, 
at 600 units per ml throughout the experiment. The effect of SBTI and heparin upon the product 
formed from the reaction between the enzymes and prokinin was tested by diluting the pro- 
kinin-enzyme mixtures with these inhibitors after  the initial 30 minute incubation period. 
The final concentration of SBTI was 250 #g per ml, and of heparin, 600 units per ml. 
The effect of plasmin and other enzymes upon crude prokinin in a globulin fraction of Hage- 
man factor-deficient plasma was tested by a similar technique. A mixture of 0.2 ml of globu- 
lin, either unheated or heated at 62°C for 30 minutes, and 0.2 ml of enzyme or buffer was 
incubated  in silicone-coated cellulose nitrate tubes  (internal diameter  15 ram) at 25°C for 
30 minutes, transferred  to an ice-bath and diluted  to 2.0 ml with buffer before injection. 
The enzymes tested were trypsin, 0.1 mg per ml, Hageman factor 4#g of protein per ml and 
plasmin, prepared by mixing an equal volume of plasminogen (3.5 units per ml) and strepto- 
kinase (2000 units per ml), the concentrations referring to the solutions before their addition 
to globulin. The globulin solution contained one-tenth volume of 5 per cent EDTA. 
In experiments with prokinin, EDTA was included in the incubation mixtures to inhibit 
any kininase which might have been present in the preparations, lest this enzyme inactivate 
kiuins which might form (26, 27). 
The Concentration of Plasminogen was measured by the method of Remmert and Cohen 
(28), as modified by Kline (29). One unit of plasminogen was that amount which, under the 
conditions of this  assay, released 450g #g of tyrosine-like material  from a  substrate of  1.5 
per cent casein in 1 hour. 
RESULTS 
The  Permeability-Enhancing  Activity  of  Plasmin.--The  preparations  of 
plasminogen tested invariably contained some active plasmin, as measured by 
their abifity to  digest casein.  Given in sufficient concentration, the intracu- 
taneous injection of such preparations increased vascular permeabifity (Table 
I). When plasminogen solutions were mixed with streptoldnase or uroldnase, 
the  permeability-enhancing activity  was  greatly  increased.  An  "effective 
blueing dose" of plasmin was approximately 0.1 unit of caseinolytic activity. 
In control experiments, streptokinase, at a  concentration of 500 units per ml, 
had no effect upon vascular permeabifity. Urokinase, at a concentration of 4000 
units per ml, slightly increased vascular permeability, while 1000 units per ml 
was without effect. 
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soybean  trypsin  inhibitor.  Similarly,  the  permeability-increasing  property  of 
spontaneously  active  plasmin,  or  plasmin  activated  by  streptokinase  or  uro- 
kinase was regularly inhibited by SBTI  at a  concentration of 125 to 250/~g per 
ml (Table II). 
T~LEI 
P~mea~ity-Enka~ingAct~ty~  ~mi~gen,  Plasmin,  Streptoki~se,  and  ~okinase 
Mixture tested* 
Plasminogen, 2.5 units per ml ....................... 
Plasminogen,  2.5  units  per  ml,  in  streptokinase,  500 
units per ml ..................................... 
Plasminogen, 0.83  units per ml,  in  streptokinase,  500 
units per ml ..................................... 
Plasminogen, 2.5 units per ml, in urokinase, 1000 units 
per ml .......................................... 
Plasminogen, 0.83 units per ml, in urokinase, 1000 units 
per ml ......................................... 
Streptokinase, 500 units per ml ..................... 
Urokinase, 4000 units per ml ....................... 
Urokinase, 2000 units per ml ....................... 
Urokinase, 1000 units per ml ....................... 
Buffer ........................................... 
Permeability activity~ 
mm 
5.7 
9.2 
6.0 
8.7 
5.3 
2.3 
4.0 
3.8 
2.8 
2.5 
* See Methods. The plasminogen preparation contained 30 per cent 
cent plasminogen, as determined by caseinolysis. 
:~ Diameter of lesion. 
phsmin and 70 per 
TABLE  II 
Inhibition  of the Permeab41ity-Enhancing Acti~d~ty of Plasmin by Soybean  Trypsin Inkibitor 
Mixture tested*  Permeability aetivity~ 
Plasminogen, 2.5 units per ml in streptokinase, 500 units 
per ml .......................................... 
Plasminogen, 2.5 units per ml in streptokinase, 500 units 
per ml and SBTI, 125 #g per ml ................... 
Plasminogen, 2.5 units per ml in urokinase, 1000 units 
per ml .......................................... 
Plasminogen, 2.5 units per ml in urokinase,  1000 units 
per ml and SBTI, 250/~g per ml ................... 
Plasminogen, 2.5 units per ml in urokinase,  1000 units 
per ml and SBTI, 125/~g per ml ................... 
~m 
8.6 
3.9 
8.7 
1.5 
5.7 
* See Methods. 
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The change induced in the skin by plasmin was transient. Within 11 minutes 
after the intracutaneous injection of streptokinase-activated plasmin, its local 
effect was drastically diminished. Mter 41 minutes, increased vascular perme- 
ability was no longer demonstrable in the injected areas (Table III). 
The activation of plasminogen by streptokinase or urokinase can be inhibited 
by epsilon aminocaproic acid. When plasminogen was incubated with strepto- 
kinase in the presence of 0.2 M epsilon aminocaproic acid, the mixture had two- 
fifths the permeability-increasing activity of a similar mixture from which the 
epsilon aminocaproic acid had been  omitted,  as  estimated by interpolation 
(Table IV). Complete inhibition was not to be expected, since the plasminogen 
solution  contained spontaneously active  plasmin,  only poorly inhibited  by 
epsilon aminocaproic acid at the concentration tested.  The permeabifity-in- 
TABLE III 
The Duration of In~reased Vascular Permeability After tke Injection of Plasmin 
Age of lesion when dye injected*  Permeability aetivity$ 
raises 
0 
6 
11 
21 
41 
~t~m 
8.3 
8.8 
4.7 
3.7 
2.3 
* A mixture of plasminogen, 2 units per ml, in streptokinase, 500 units per ml, was in- 
cubated at 25°C in cellulose  nitrate tubes for 15 minutes and then stored in ice. At intervals, 
0.1 ml aliquots were injected into guinea pigs before  and just after the intravenous injection 
of pontamine sky blue. 
Diameter of lesion. 
creasing property of plasmin was not inhibited by two intraperitoneal injec- 
tions of epsilon aminocaproic acid, in a dose of 1 gm per kilo of body weight, 
45 and 15 minutes before. 
Experiments on the Mode of Action of Plasmin in Increasing Vascular Perme- 
ability.--In earlier studies, the suggestion was made that plasmin can change 
the first component of complement to a hydrolytic enzyme, C'I esterase (30). 
C'I esterase increases vascular permeabifity in guinea pig skin, an effect in- 
hibited by the intravenous injection of triprolidine (31).  In contrast, triproli- 
dine did not inhibit the permeability-enhancing activity of plasmin (Table V). 
Preparations of partially purified activated Hageman factor increase vascu- 
lar permeabifity (21).  One explanation for the effect of plasmin might be its 
contamination with activated Hageman factor. The effective blueing dose of 
preparations  of Hageman factor used in previous experiments was approxi- 
mately 0.02 to 0.04 units per 0.1 ml (21).  In contrast, the amount of Hageman 912  VASCIYLAR PEP.,MEABII,ITY AND PLASMIN 
factor contaminating the plasminogen preparations was approximately 0.00005 
units per 0.1 ml. It seems unlikely, therefore, that the effect of plasmin could be 
attributed to its content of this clotting factor. 
A  more sensitive test for contamination of the plasminogen with activated 
TABLE IV 
The  Effect of Epsilon  Aminocaproic Acid  Upon the Permeability-Enkarxing  Properties  of 
Plasmin 
Mixture tested*  Permeability  activity~: 
Plasminogen,  1.6 units per  ml,  in streptokinase,  500 
units per ml ..................................... 
Plasminogen, 0.55 units per  ml, in streptokinase,  500 
units per ml .................................... 
Plasminogen, 1.6 units per ml, in buffer .............. 
Plasminogen,  1.6 units per ml,  in streptokinase,  500 
units per ml and epsilon aminocaproic acid, 0.2 ~s... 
Buffer ........................................... 
mm 
7.5 
4.0 
4.0 
5.0 
2.5 
* See Methods. The plasminogen preparation contained approximately 15 per cent plasmin 
and 85 per cent plasminogen, as determined by caseinolysis. 
Diameter of lesion. 
TABLE V 
The Effect of Intravenously Injected Triprolidine Upon the Vascular Permeability-Enhancing 
Properties of Plasmin 
Mixture tested* 
Histamine diphosphate, 55 #g per ml ................. 
Plasminogen, 2 units per ml, in streptokinase, 500 units 
per ml .......................................... 
Plasminogen, 2 units per  ml, in urokinase,  1000 units 
per ml .......................................... 
Buffer... 
Permeability  activity~ 
Triprolidine 
mm 
3.0 
9.8 
8.8 
2.7 
Buffer 
~m 
9.2 
8.8 
9.2 
2.7 
* See Methods. 
Diameter of lesion. 
Hageman factor took advantage of the observation that this clotting factor can 
activate  the  permeability factor  in  human  plasma  designed  by  Miles  and 
Wilhelm as PF/Dil (25). An amount of plasminogen was chosen which of itself 
was  insufficient to  produce  a  measurable increase  in  vascular permeability 
without the addition of streptokinase. This amount of plasminogen, 1 unit per OSCAR  D.  RATNOFF  913 
ml, was incubated for 24 minutes at 37°C with an equal volume of Hageman 
factor-deficient plasma,  diluted 50-fold with buffer in silicone-coated cellulose 
nitrate tubes. No permeability-enhancing activity evolved, as tested 0, 12, and 
24 minutes after the mixtures were prepared. In contrast, a mixture containing 
1  ~g of partially activated Hageman factor in  100-fold diluted  Hageman fac- 
tor-deficient plasma had sufficient permeability-enhancing activity to produce 
an area of blueing 8.1  mm in diameter in  12 minutes.  Presumably,  then,  the 
TABLE VI 
The  Effect of  Trypsin,  ltageman  Factor, and  Plasmin  Upon  the  Permeabilily-Enhancing 
Properties of Crude "Prokinin":  Influence of Inhibitors 
Agents incubated with "prokinin" 
and enzyme* 
Buffer 
SBTI, 250 ~g per ml§ 
Buffer 
Heparm, 600 units per ml§ 
Buffer 
Diluent added after incubation* 
Buffer 
SBTI, 250/zg per ml[[ 
SBTI, 250/zg per ml[[ 
Heparin, 600 units per ml[[ 
Heparin, 600 units per ml[[ 
Permeability activity~ 
Tr~p- Hage-  Plas- 
sln  mau  Bu~el  factor  min 
8.6  7.0  7.9  3.4 
3.0  2.8  3.4 
8.0  3.0  8.0 
4.0  3.6  3.5 
8.1  4.O  7.0 
* A mixture of 0.18 ml of "prokinin",  0.02 ml 5 per cent EDTA, 0.1 ml of the enzyme to 
be tested  and 0.1 ml of buffer, SBTI or heparin  was incubated  in silicone-coated tubes  at 
25°C for 30 minutes  (See Methods).  The mixtures were then diluted  to 2.0 ml with buffer 
or solutions of SBTI or heparin,  and injected  into guinea pigs. The enzymes tested  were 
trypsin, 0.1 nag per ml, Hageman factor, 8/zg protein per ml, and a mixture of plasminogen, 
1.75 units per ml in streptokinase,  1000 units per ml. The concentrations  of these enzymes 
refer to the solutions before their addition to prokinin. 
Diameter of lesion. 
§ Concentration in the initial mixture. 
[] Concentration in the final mixture. 
permeability-increasing  property  of  plasmin  could  not  be  attributed  to its 
contamination with activated Hageman factor. 
Plasmin has been said to bring about the formation of plasma kinins, either 
by  digestion  of  their  precursor,  prokinin,  or  by  changing  kallikreinogen  to 
kaUikrein. In this way~ plasmin is apparently similar in behavior to trypsin. 
When a  fraction of human plasma thought to be rich in prokinin, prepared 
by a  technique derived from that of Webster and Pierce, was incubated with 
trypsin, the mixture acquired the property of increasing vascular permeability 
(Table V-I). This effect was prevented by SBTI or heparin, but these substances 
did not block the  agents  which evolved from the  action of trypsin.  In some 
preparations of crude proldnin, such as that used in the experiment summarized 914  VASCULAR  PERMEABILITY  AND  PLASMIN 
in Table VI, permeability-increasing activity also evolved upon incubation with 
Hageman factor.  Other preparations  of prokinin  made by the  same method 
lacked this last property. The evolution of this activity was prevented by SBTI 
and heparin. Moreover, the agent which appeared in mixtures of prokinin and 
Hageman factor was inhibited  by SBTI and heparin,  distinguishing  it from 
that  which  appeared in mixtures of prokinin and  trypsin. 
Permeability-increasing activity also appeared when the same preparations 
of prokinin were incubated with streptokinase-acfivated plasmin (Table VI). 
The development of this activity was inhibited by SBTI and heparin, but once 
it had evolved, these agents did not block its effect upon guinea pig skin. Thus 
the effect of plasmin was similar to that of trypsin, but unlike that of Hageman 
TABLE  VII 
The  Effect  of  Trypsin,  Hageman  Factor,  and  Plasmin  Upon  the  Permeability-Enhancing 
Properties  of a Globulin Fraction  of Plasma 
Fraction incubated with enzyme* 
Unheated globulin  .......................... 
Globulin heated 62°C, 30 minutes ............ 
Buffer  ..................................... 
Permeability activity~ 
Trypsin  Hagemsn  "  Buffer  f~¢~cr  PI~ smln 
7.5  8.1  6.8  3.0 
8.3  3.4  6.8  2.9 
2.9  /  3.0  I  3.6  t  2.S 
* A mixture of 0.2 ml globulin or buffer was incubated at 25°C for 30 minutes in silicone- 
coated tubes with 0.2 ml enzyme or buffer, and then diluted to 2.0 ml with buffer, before 
injection (see Methods). The enzymes tested were trypsin 0.1 mg per ml, Hageman factor, 
4 #g protein per ml, and a mixture of plasminogen, 2.5 units per ml in streptokinase, 1000 
units per ml, the concentrations referring to the solutions before their addition to globulin. 
Diameter of lesion. 
factor. In the concentrations tested, neither prokinin, plasminogen, nor strepto- 
kinase alone had a measurable effect. 
The effect of plasmin upon a prokinin fraction of plasma could have been in- 
direct,  for it was not possible to exclude the presence of kallikreinogen. The 
following  experiment  suggests  that  plasmin  can  induce  the  formation  of  a 
permeability-increasing agent in plasma depleted of this proenzyme. 
A globulin fraction was prepared from plasma deficient in Hageman factor 
and was incubated at 62°C for 30 minutes, a procedure designed to inactivate 
kallikreinogen.  When  this  fraction was incubated  with  trypsin,  the  mixture 
acquired the capacity to increase vascular permeability (Table VII). Similarly, 
a mixture of streptokinase-acfivated plasmin and the heated globulin increased 
vascular  permeability.  No  such  activity  evolved  when  partially  activated 
Hageman factor was incubated with the heated globulin fraction. In contrast, OSCAR D.  RATNOFF  915 
a mixture of Hageman factor and an unheated globulin fraction enhanced vascu- 
lar permeability. These experiments demonstrate that plasmin can act upon an 
agent or agents not affected by activated I-Iageman factor. They do not prove 
that plasmin acts in the absence of kallikreinogen,  since traces of this agent may 
have survived the heating process. 
DISCUSSION 
In the experiments reported here, human plasmin regularly increased vascu- 
lar permeabilityin the skin of guinea pigs. Plasmin also induced the formation of 
permeability-increasing agents in a fraction of plasma containing the precursors 
of the kinins. 
Under experimental conditions, a number of biologically  active polypeptides 
may appear  to be generated within human plasma.  These polypeptides, the 
kinins,  increase vascular permeability,  dilate blood vessels,  contract smooth 
muscles, induce pain, and provoke the migration of leukocytes into extravascu- 
lar tissues (1). Three peptides have been identified, bradykinin (32),  kallidin 
(33), and methionyl-lysylbradykinin (34), and still others may exist (35). The 
elaboration of kinins at the site of injury seems to explain some of the phe- 
nomena of the inflammatory reaction. In agreement with this view, kinins have 
been identified in experimental inflammatory exudates (36, 37) and in fluid ob- 
tained from inflamed joints (38, 39). 
The kinins are thought to be derived from a precursor in the globulin fraction 
of plasma (40). They are apparently liberated when this precursor, prokinin, is 
partially  hydrolyzed by the kallikreins,  a  group  of one or several proteases 
found in saliva, snake venom (a specialized  type of saliva), pancreatic juice, 
urine, and other secretions (1). Kinins can also be elaborated from their precur- 
sor through  the action of trypsin (41)  or of a  specific proteolytic enzyme in 
plasma itself, plasma kallikrein (42). In freshly shed blood, kallikrein existsin 
an inactive form, kallikreinogen  (42). The activation of plasma kallikreinogen 
can be brought about in several ways. For example,  treatment of plasma with 
acetone (42) or trypsin (41) results in the activation of kallikreinogen.  Thus, 
trypsin appears to liberate kinins both by a direct action upon prokinin and in- 
directly, through the formation of plasma kaUikrein. 
KaUikreinogen  can also be activated by exposing  plasma to glass surfaces. 
The effects of acetone and of glass appear to depend upon the presence in plasma 
of a clotting factor, Hageman factor (43, 44). This agent is present in freshly 
shed blood in an inert form, but it can be activated by contact with certain 
suitable insoluble substances (45, 46) or by the addition of solutions of ellagic 
acid (47). The effect of activated Hageman factor upon kallikreinogen  may be 
indirect,  for it has  been found to activate  still  another  hydrolytic enzyme, 
variously known as PF/Dil and plasma permeability factor, which can increase 
vascular permeability in guinea pig skin.  Perhaps the sequence of events when 916  VASCULAR  PERMEABILITY  AND  PLASMIN 
plasma comes in contact with glass is the successive activation  of Hageman 
factor, PF/Dil and kallikreinogen,  leading  ultimately to the elaboration of the 
kinins. 
As one might expect, the intracutaneous injection of the active form of any of 
the agents in this chain of reactions increases vascular permeability. Thus, the 
injection of activated Hageman factor, PF/Dil, kallikrein,  or bradykinin aug- 
ments vascular permeability. Under some conditions, these various permeability 
factors can be distinguished by suitable assays. 
The mechanisms  through  which plasmin  exerts its permeability-increasing 
effect was explored by techniques designed to distinguish its action from those 
of other known permeability factors. Plasminogen,  the precursor of plasmin, 
had only such permeability-increasing activity as could be accounted for by the 
fraction of plasmin invariably present.  Once plasminogen  had been activated 
by streptokinase or urokinase,  the plasmin which evolved enhanced vascular 
permeability.  SBTI, which blocks the action of plasmin,  inhibited its effect 
upon guinea pig skin. Epsilon aminocaproic acid,  at the concentrations tested, 
is known to inhibit  the activation of plasminogen,  but has little effect upon 
plasmin.  In agreement with this,  this inhibitor was only partially effective in 
blocking the permeability-increasing properties of plasmin. 
The experiments just summarized make it unlikely that the permeability-in- 
creasing properties of plasmin were due to contamination  of the plasminogen 
preparation with other permeability factors. Among those described in human 
plasma  are  Hageman  factor,  PF/Dil,  kallikrein,  PF/Nat,  PF/P,  and  C'I 
esterase. 
The preparation of plasminogen tested contained traces of Hageman factor, 
but these were far less than the amount needed to increase vascular permeability 
in guinea pig skin (21), and were insufficient  to induce the formation of PF/Dil 
in diluted human plasma.  Nor could the effect of streptokinase or urokinase 
upon the preparation of plasminogen be attributed to an action upon Hageman 
factor, since the activity of this procoagulant substance is not enhanced by these 
agents. 
The fact that its activity was greatly enhanced by streptokinase and uro- 
kinase separated plasmin from PF/Dil,  which is unaffected by these agents. 
That human plasmin is not PF/Dil has previously been shown by Mill and his 
colleagues  (48). Nor can plasmin be identified with kallikrein  (4, 9). Recently, 
McConnell,  Kagen, and Becker (49) have shown that heparin,  at a concentra- 
tion of 600 units per ml, will not inhibit the permeability-increasing activity of 
kallikrein.  In the present study, the effect of plasmin was completely blocked 
by preparations of heparin at this concentration. Whether the inhibitory effect 
was due to heparin itself or to some contaminant  in the preparation was not 
examined. 
The permeability-increasing activity of our preparations was clearly separa- OSCAR I). ~TNO~F  917 
ble  from that of PF/Nat, a  permeability factor found in undiluted human 
plasma (20), because it was inhibited by SBTI and its effect lasted only a matter 
of minutes. It was distinguishable  from PF/P which is elicited by exposure of 
guinea pig serum to antigen-antibody aggregates,  since the latter is partially 
inhibited by the intravenous injection of antihistaminic agents,  and,  unlike 
plasmin, has a prolonged action after its injection into guinea pig skin (50). 
Still another permeability factor which can be derived from human plasma 
is C'I esterase, a hydrolytic enzyme which evolves during the activation of the 
first  component  of  complement.  The  permeability-increasing  properties  of 
C'I esterase are inhibited by the intravenous injection of triprolidine,  an anti- 
histaminic agent (31). Failure of triprolidine  to block  the action of plasmin 
distinguished its effect from that of C'I esterase and made it unlikely that its 
action was mediated through the activation of the first component of comple- 
ment.  This  observation is particularly pertinent,  since  evidence  exists  that 
plasmin can convert the first component of complement to C'I esterase (30). 
The possibility that plasmin exerted its effect by liberating kinins from their 
precursor, prokinin, was explored. The same amount of permeability-increasing 
activity evolved when plasmin was incubated with an unheated globulin frac- 
tion of plasma,  as with one which had been heated at 62°C for 30 minutes, a 
procedure designed to decrease its content of kallikreinogen (18) and the precur- 
sor of PF/Dil (20, 21). Were kallikrein required for this action of plasmin, one 
might expect  the heated globulin  to produce  a  smaller lesion.  Permeability- 
enhancing activity also  appeared when  plasmin  was  incubated with a frac- 
tion of plasma rich in prokinin which was prepared by column  chromatogra- 
phy. The permeability factors which developed under  these  conditions were 
not inhibited by SBTI, distinguishing them from kallikrein (18, 51)  or PF/ 
Dil (20, 25), but not from non-enzymatic molecules like bradykinin (9). 
The experiments  described are in agreement with previous reports that plas- 
rain (5,  7), like trypsin (41), can induce kinin-like activity by a direct action 
upon prokinin. They do not exclude an additional effect upon kallikreinogen, 
with which our prokinin preparations may have been unwittingly  contaminated. 
Back (52) and Vogt  (8)  have described experiments  which  they interpret to 
mean that plasmin can convert kallikreinogen  to kallikrein.  No direct test of 
this possibility was made. 
The observation that plasmin enhances vascular permeability is by no means 
surprising,  since this enzyme has been shown to bring about the formation of 
agents which contract smooth muscle and dilate blood vessels (2-8).  What is 
surprising is that earlier investigators failed to note the effect of plasmin upon 
vascular permeability. A likely explanation is that the preparations previously 
tested consisted principally of streptokinase and had little plasmin-like activity. 
The degree to which plasmin may participate in the inflammatory  reaction is 
not clarified by the present experiments.  The concentration of plasmin which 918  VASCULAR  PERMEABILITY AND  PLASMIN 
was capable of increasing vascular permeability was approximately 1 Remmert 
and  Cohen unit per ml.  This is  considerably less  that  the  concentration of 
plasmin which might be generated in plasma. But plasma contains several in- 
hibitory substances which can block its activity. Whether sufficient plasmin 
may become activated in areas of inflammation to a degree sufficient to over- 
come these inhibitors,  and  thus  to contribute to the pathologic changes ob- 
served remains to be determined. 
SUMMARY 
Preparations of plasminogen,  soluble in aqueous media, increased vascular 
permeability in guinea pig skin when activated by streptokinase or urokinase. 
The permeability-enhancing effect was inhibited by soybean trypsin inhibitor 
but not by triprolidine. Permeability-enhancing activity evolved when plasmin 
was incubated with fractions of plasma rich in prokinin. The experiments de- 
scribed suggest that plasmin exerts its permeability-increasing effect through 
the elaboration of kinins. 
The experiments  described were made possible by the expert technical assistance of Miss 
Gloria Bauer, Miss Linda Graham, Mrs. Marjorie Smink, and Mrs. Edna Stone. Dr. Arnold 
Powell determined the nitrogen content of our plasminogen preparations. Dr. L H.  Lepow 
assayed the plasminogen preparation for C'I esterase and Cq subcomponents. 
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